GITNUXSOFTWARE ADVICE
Science ResearchTop 10 Best Process Development Services of 2026
Rankings of top process development services for biopharma teams, comparing Lonza, Samsung Biologics, and Thermo Fisher for key criteria and tradeoffs.
How we ranked these tools
An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.
AI search agents find sources, extract figures with provenance, and aggregate written reviews. They also transcribe video reviews and podcasts.
Framework: Features 40% · Ease 30% · Value 30%
Gitnux may earn a commission through links on this page — this does not influence rankings. Editorial policy
Lonza is the best pick for regulated development teams that need integrated execution support because its program delivery links design space and risk assessment outputs into tech transfer packages for manufacturing handoff, while Evotec is a strong alternative for biopharma teams wanting tightly linked characterization and analytics feeding transfer-ready decisions.
Editor’s top 3 picks
Three quick recommendations before you dive into the full comparison below — each one leads on a different dimension.
Lonza
Program delivery that links design space studies and risk assessment outputs into tech transfer packages for manufacturing handoff.
Best for: Fits when regulated development teams need integrated execution support across characterization, methods, and technology transfer.
Samsung Biologics
Editor pickTechnology transfer execution that links experiment outcomes to batch record translation and scale-ready process documentation.
Best for: Fits when teams need manufacturing-relevant process development evidence and transfer-ready documentation for submission timelines.
Thermo Fisher Scientific
Editor pickInstrumentation-driven process analytical technology studies tied directly to control strategy recommendations and report traceability.
Best for: Fits when regulated teams need integrated process development plus validated analytics for technology transfer.
Comparison Table
Lonza
enterprise_vendorIntegrated pharma process development and manufacturing services from clinical to commercial scale.
Program delivery that links design space studies and risk assessment outputs into tech transfer packages for manufacturing handoff.
Lonza delivers process development services spanning formulation development, analytical method development, and tech transfer toward clinical and commercial manufacturing. Teams get end-to-end support that connects process characterization, design space exploration, and risk assessment outputs into documentation for regulatory-facing workflows.
The key distinction is deep operational capability across biologics and small-molecule programs, with scale-up and scale-down guidance geared to manufacturing execution needs. Delivery quality shows up in how work products map to execution artifacts like batch record inputs and process development reports.
- +Cross-domain process development coverage from formulation to tech transfer
- +Analytical method development aligned to characterization and regulatory documentation needs
- +Practical scale-up planning that ties experiments to manufacturing execution constraints
- +Clear risk assessment outputs used to shape control strategy decisions
- –Engagement requires strong internal coordination to keep inputs and change control aligned
- –Process characterization depth can vary by program maturity and available internal samples
- –Automation and API surfaces are not a primary delivery mechanism
- –Document turnaround cadence depends on site scheduling and analytical workload
Best for: Fits when regulated development teams need integrated execution support across characterization, methods, and technology transfer.
Samsung Biologics
enterprise_vendorLarge-scale biologics process development and CDMO services.
Technology transfer execution that links experiment outcomes to batch record translation and scale-ready process documentation.
Samsung Biologics supports end-to-end process development workflows that start with defining process parameters and mapping them to product quality behavior through structured characterization studies. The engagement model typically covers process characterization, risk assessment inputs for a control strategy, and execution of experiments designed to inform design space and scale transitions. The quality of delivery tends to track manufacturing realities such as equipment capability, mixing and mass transfer effects, and feasibility of batch record translation into standard operating procedure style workflows.
A tradeoff is that deep domain execution can require tighter alignment on internal material, analytical capacity, and facility assumptions to keep timelines consistent with pilot to commercial transfer expectations. Samsung Biologics fits teams that need a development partner capable of producing technology transfer-ready process documentation and scale transition evidence for a regulatory submission dossier rather than only early lab optimization data.
- +Practical scale transition work tied to manufacturing equipment constraints
- +Structured characterization outputs that support process understanding and control strategy drafting
- +Analytical method development support aligned with process sampling workflows
- +Transfer-focused documentation designed to feed batch record and SOP authoring
- –Requires strong alignment on upstream materials and testing logistics
- –Documentation depth can lag if decision gates are delayed internally
- –Speed can depend on facility scheduling for pilot experiments
- –Limited transparency into experiment planning details without frequent review touchpoints
CMC and process development teams
Plan characterization studies for parameter-to-quality links
Defensible process understanding
Regulatory submission owners
Assemble transfer evidence for dossier-ready documentation
Cohesive submission package
Show 1 more scenario
Analytical development leads
Align sampling and method work with process changes
Comparable measurement datasets
Analytical method development supports process experiments without breaking sample comparability.
Best for: Fits when teams need manufacturing-relevant process development evidence and transfer-ready documentation for submission timelines.
Thermo Fisher Scientific
enterprise_vendorProcess development services through the Patheon brand covering small molecules and biologics.
Instrumentation-driven process analytical technology studies tied directly to control strategy recommendations and report traceability.
Thermo Fisher Scientific supports process characterization through structured design of experiments and quantified risk assessment outputs that feed control strategy decisions. Analytical method development and method validation are handled alongside process development so results map directly into a process development report narrative and the batch record inputs needed for later stages. Integration is strongest when the development plan specifies both critical process parameters and critical quality attributes and assigns owners for each experimental thread.
A tradeoff exists when organizations require a highly specific, internal data model or strict integration into existing LIMS and ELN workflows because Thermo Fisher Scientific’s process artifacts follow its own standardized documentation patterns. The provider fits best for situations that need scale-up and technology transfer planning tied to comparability evidence rather than standalone chemistry or standalone testing.
- +Tight coupling of development experiments with analytical method validation workstreams
- +Documented experimental workflow supports reproducibility across study phases
- +GMP-facing deliverables map to batch record and SOP generation needs
- +Strong instrumentation and process analytical technology integration for monitoring
- –Requires disciplined study scoping to avoid rework between lab and report cycles
- –Less suited for teams needing plug-in integration with internal data capture systems
CMC and process development teams
Define control strategy from characterization data
Sharper CPP and CQA alignment
Analytical development leads
Validate methods alongside formulation runs
Faster readiness for later stages
Show 2 more scenarios
Technology transfer program managers
Scale-up with comparability evidence
Reduced transfer technical gaps
Scale-up studies include comparability-focused outputs that support transfer documentation.
Regulatory submission owners
Assemble a process development report package
Cleaner dossier narrative flow
Development artifacts are produced in a documentation structure aligned to submission expectations.
Best for: Fits when regulated teams need integrated process development plus validated analytics for technology transfer.
WuXi AppTec
enterprise_vendorProcess development services for small molecules, biologics, and cell therapies.
Integrated CMC execution that links process characterization outputs to analytical validation evidence and transfer-ready documentation packages.
WuXi AppTec supports process characterization work that feeds into design space definitions, and it connects those outputs to batch execution planning and process control documentation. The provider also runs analytical method development and method validation activities that are needed to generate release and stability evidence for process change decisions. Teams get a single program interface spanning upstream or chemical synthesis steps, downstream or formulation work where relevant, and the supporting analytical workstreams.
- +Converges process work and analytical evidence into one development storyline
- +Structured tech transfer artifacts support controlled scale-up and documentation
- +Works across multiple modalities with consistent CMC execution discipline
- +Handles method validation work needed for release and stability readouts
- –Requires disciplined sponsor governance to manage cross-workstream change control
- –Project timelines depend on analytical turnaround and sample availability
Best for: Fits when a sponsor needs coordinated process and analytical execution for transfer and validation readiness.
Evotec
specialistProcess development services spanning discovery through commercial manufacturing.
Study plans that connect critical process parameters to measurable performance shifts across development stages.
Evotec delivers process development services tied to pharmaceutical discovery-to-development workflows, with a focus on executing experimentally grounded development plans. The distinct strength is end-to-end support that connects formulation and analytical work with process characterization, so development decisions reflect measurable outputs.
- +Ties experimental process characterization to practical development decisions
- +Supports analytical method development aligned to process and product outcomes
- +Uses structured documentation outputs for downstream technology transfer
- +Handles multi-stage work spanning feasibility through scale-up planning
- –Deliverables and timelines depend on scope clarity and sample availability
- –Documentation depth can increase administrative overhead for distributed teams
- –Some specialized characterization work may require external lab scheduling
- –Integrated automation coverage varies by site and project requirements
Best for: Fits when biopharma teams need tightly linked process characterization, analytical development, and transfer-ready documentation.
Curia
specialistProcess development and manufacturing services for small molecules and biologics.
Experiment-to-decision reporting that maps executed runs to process parameter changes and downstream handoff artifacts.
Curia provides process development services with a biotech and pharmaceutical delivery focus, emphasizing technically detailed characterization work and documentation outputs used in regulated development programs. Teams typically use Curia for process design, optimization, and technical transfer support across development stages that feed into downstream regulatory-ready artifacts.
- +Strong experimental planning and run traceability for development decisions
- +Clear process documentation structure for cross-team reviews
- +Practical scale-up and technology transfer support for manufacturing handoffs
- +Deep domain coverage across development workflows that touch QA deliverables
- –Requires the client to maintain tight inputs, timelines, and review cadence
- –Automation and API surface for data integration is not a primary delivery artifact
- –Turnaround depends on lab execution scheduling and internal review cycles
- –Limited evidence of configurable governance controls for distributed teams
Best for: Fits when regulated process development needs experiment-driven decisions and audit-ready documentation handoffs.
Cambrex
specialistAPI process development and scale-up services for pharmaceutical manufacturers.
Integrated development-to-transfer documentation that ties experiments, analytical results, and control strategy into a single tech transfer-ready package.
Cambrex runs process development and technical transfer work for small-molecule and biologics manufacturing, with deliverables designed for regulated change control. Strength is the ability to convert lab-scale studies into validated, scalable manufacturing steps that feed directly into process development reports and tech transfer packages.
- +Regulated tech transfer packages that map process steps to documentation expectations
- +Analytical method development support tied to impurity profiling and specification setting
- +Experiment planning and risk assessment artifacts usable for control strategy narratives
- +Experience running scale-up work that reduces downstream validation surprises
- –Governance-heavy handoffs can slow iteration when requirements change midstream
- –Automation and API integration for internal data systems is not a primary delivery surface
- –Large, cross-study programs can require tighter planning than smaller proof-of-concept efforts
- –Some advanced modeling artifacts depend on the agreed workflow and scope boundaries
Best for: Fits when regulated process development teams need execution across analytical work, scale-up, and validation support.
Aragen Life Sciences
specialistProcess development and contract research services for pharmaceutical and biotech clients.
Process development report deliverables that connect experimental observations to control strategy draft decision logic.
Aragen Life Sciences delivers process development services for biologics and small molecules, with a track record centered on experimental execution, characterization, and scale-up planning. The engagement model typically maps method and process experiments into a documented process development report, linking observed behavior to design space decisions and control strategy drafts.
- +Strong execution of process characterization experiments tied to documented decision points
- +Clear linkage between risk assessment outputs and draft control strategy elements
- +Manufacturing-facing documentation artifacts support later tech transfer work
- +Experienced coordination of analytical method development alongside process experiments
- –Governance for cross-study change control depends on client process maturity
- –Automation and API integration depth is not a productized interface layer
- –Turnaround for iterative DoE cycles is sensitive to inbound analytical readiness
- –Limited evidence of self-serve dashboards for experiment status and audit trails
Best for: Fits when teams need hands-on process development execution plus manufacturing-oriented documentation.
Almac Group
specialistProcess development and scale-up services for API and drug product manufacturing.
Single engagement teams align analytical method readiness with process scale-up evidence for transfer decisions.
Almac Group serves process development teams that need end-to-end chemistry, manufacturing, and analytical execution with scientific staff embedded in regulated workflows. Its core capabilities span process characterization, analytical method development and validation, and support for technology transfer into pilot and commercial manufacturing contexts.
- +Cross-functional delivery links process work to analytical method development timelines
- +Documented, regulated workflow orientation supports consistent process development reporting
- +Strong analytical execution reduces rework during method validation and transfer
- +Experienced teams support risk assessment outputs used in control strategy discussions
- –Change requests can require more governance time than internal teams expect
- –Deep involvement is often needed to map client requirements into execution plans
- –Analytical scope coverage can lag when projects demand broad multi-matrix testing
- –Integration with internal lab systems may rely on structured manual handoffs
Best for: Fits when drug teams need integrated process and analytical delivery for regulated technology transfer milestones.
Quotient Sciences
specialistProcess development and clinical trial manufacturing services for drug products.
Integrated development-to-reporting workflow that turns characterization findings into a structured process development report used for later regulatory steps.
Quotient Sciences delivers process development services that connect experimental work to regulatory-ready documentation for chemistry, manufacturing, and controls. Its core capability centers on designing and executing process development activities for biologics and related modalities, then translating outcomes into control strategy artifacts used in submissions.
- +Regulated documentation workflow supports consistent handoff to submission teams
- +Process characterization execution tied to critical process parameters and controls
- +Analytical method development support reduces cross-team alignment gaps
- +Operational traceability strengthens audit readiness for development activities
- –Integration depth can be limited if internal systems require custom data plumbing
- –Turnaround depends on experimental throughput and method readiness constraints
- –Complex design space work may require tighter study design governance
- –Change control discipline is needed to prevent downstream rework
Best for: Fits when teams need end-to-end process development that outputs submission-ready development reporting artifacts.
Conclusion
After evaluating 10 process development, Lonza stands out as our overall top pick — it scored highest across our combined criteria of features, ease of use, and value, which is why it sits at #1 in the rankings above.
Use the comparison table and detailed reviews above to validate the fit against your own requirements before committing to a tool.
How to Choose the Right Process Development
Process development buyers in biopharma usually need more than experiment execution, because Lonza, Samsung Biologics, Thermo Fisher Scientific, and WuXi AppTec shape the evidence trail that later supports tech transfer and regulatory documentation. This guide covers Lonza, Samsung Biologics, Thermo Fisher Scientific, WuXi AppTec, Evotec, Curia, Cambrex, Aragen Life Sciences, Almac Group, and Quotient Sciences, with decision notes tied to how each provider links characterization work to handoff artifacts.
The selection tradeoffs tend to concentrate on which party owns the transition from process understanding to documented process controls, including Analytical method development, batch record translation, and control strategy draft logic. The guide frames those differences around integration depth across workstreams and the degree to which study outputs become transfer-ready documentation for later execution phases.
Process Development services that convert process characterization into transfer-ready controls
Process development is the work that connects process characterization evidence to downstream decisions like critical process parameters, control strategy direction, and tech transfer package readiness. Lonza delivers an execution storyline that links design space studies and risk assessment outputs into manufacturing handoff materials, which helps teams keep decisions aligned across multiple workstreams.
Samsung Biologics emphasizes technology transfer execution by translating experiment outcomes into batch record-ready and scale-ready process documentation, which supports manufacturing relevance during submission timelines. Thermo Fisher Scientific and WuXi AppTec focus more on instrumentation-driven analytical development tied directly to control strategy recommendations, which can improve traceability but increases the need for disciplined study scoping and tight sample and logistics alignment.
Process Development delivery traits that shape transfer-ready controls
Process development services matter most when they turn process characterization evidence into downstream documentation that teams can execute under GMP, like a process development report, a draft control strategy, and transfer-ready handoff materials. The providers listed below differ less in whether they run studies and more in how they connect study outputs to tech transfer decisions.
Lonza links design space work and risk assessment outputs into manufacturing handoff packages, while Samsung Biologics connects experiment outcomes to batch record translation and scale-ready process documentation. Thermo Fisher Scientific and WuXi AppTec emphasize instrumentation-driven process analytical technology studies that feed directly into control strategy recommendations, and each path changes the level of scoping discipline needed to avoid rework.
Tech transfer package linkage from characterization and risk work
Lonza ties design space studies and risk assessment outputs into manufacturing handoff materials for transfer decisions. WuXi AppTec converges process characterization outputs with transfer-ready documentation for execution readiness.
Batch record translation and scale-ready documentation support
Samsung Biologics executes technology transfer by translating experiment outcomes into batch record-ready and scale-ready process documentation. Thermo Fisher Scientific emphasizes study traceability tied to control strategy recommendations as part of that transfer evidence chain.
Instrumentation-driven process analytical technology tied to control strategy
Thermo Fisher Scientific runs instrumentation-focused process analytical technology studies that connect to control strategy recommendations with report traceability. Curia drives experiment-to-decision reporting that maps executed runs to parameter changes that support downstream handoff artifacts.
Analytical method development alignment with process characterization outcomes
Lonza keeps analytical method development aligned to characterization and regulatory documentation needs across the program. Cambrex ties analytical method development support to impurity profiling and specification setting to support regulated tech transfer.
Execution storyline that converges process and analytical evidence
WuXi AppTec builds one development storyline by linking process work and analytical evidence into one transfer narrative. WuXi AppTec also documents structured tech transfer artifacts that support controlled scale-up and documentation.
Decide who owns the transition from characterization evidence to process controls
Most process development engagements succeed when one party consistently connects process characterization results to decision points like critical process parameters, control strategy direction, and transfer documentation readiness. The main choice is whether that linkage is delivered as an integrated storyline across workstreams or as more specialized analytical or reporting outputs.
Teams also need to pick based on internal governance load and change control discipline because providers like Lonza and WuXi AppTec expect coordinated inputs to keep transition artifacts aligned. Other providers, like Curia and Cambrex, emphasize experiment planning and run traceability or regulated tech transfer package structure, and those approaches shift the burden to clients for cadence and input management.
Select the linkage depth that matches the internal change-control model
If internal teams need one continuous evidence trail from design space and risk work into manufacturing handoff, choose Lonza because program delivery connects those outputs into tech transfer packages. If cross-workstream change control is likely to strain internal governance, choose a provider that converges evidence but still requires aligned decision gates, like WuXi AppTec, since project timelines depend on analytical turnaround and sample availability.
Choose the reporting and traceability shape that feeds your tech transfer gate reviews
If gate reviews demand run-level traceability mapped to parameter changes and downstream artifacts, choose Curia because it provides experiment-to-decision reporting that maps executed runs to process parameter changes and handoff artifacts. If gate reviews focus on regulated tech transfer expectations across analytical, scale-up, and validation support, choose Cambrex because it ties experiments, analytical results, and control strategy into a single tech transfer-ready package.
Match the analytical development role to how your control strategy draft is built
If control strategy direction depends on instrumentation-driven process analytical technology studies with tight study-to-report traceability, choose Thermo Fisher Scientific because it ties instrumentation studies directly to control strategy recommendations. If the program needs integrated CMC execution that links process characterization outputs to analytical validation evidence and transfer-ready documentation, choose WuXi AppTec.
Pick the scaling documentation handoff approach based on manufacturing constraint realism
If manufacturing relevance depends on structured translation into batch record-ready and scale-ready process documentation, choose Samsung Biologics because technology transfer execution includes batch record translation tied to manufacturing equipment constraints. If the program prioritizes analytical method readiness alignment alongside process scale-up evidence for regulated technology transfer milestones, choose Almac Group because its single engagement teams align those timelines.
Decide whether the engagement ends at a process development report or extends through transfer-ready artifacts
If the critical outcome is a structured process development report that connects characterization findings to later regulatory steps, choose Quotient Sciences because it focuses on integrated development-to-reporting workflow that produces that report used for later regulatory steps. If the program needs the decision logic link from risk outputs into a control strategy draft, choose Aragen Life Sciences because its deliverables connect experimental observations to control strategy draft decision logic.
Who benefits from these Process Development delivery models
Biopharma teams typically need process development services that reduce uncertainty in later stages by producing transfer-ready documentation, not just experiment results. The fit depends on how much integration depth the team needs across characterization, analytical method development, and technology transfer artifacts.
The providers below fit different operational realities, including sample logistics constraints, governance burden for cross-workstream change control, and the degree to which validated analytics must be part of the transfer evidence package.
Regulated biopharma teams building tech transfer packages from both design space and risk outputs
Lonza fits teams that need integrated execution that links design space studies and risk assessment outputs into manufacturing handoff materials for regulated handoff.
Manufacturing-focused teams that need batch record translation and scale-ready documentation tied to equipment constraints
Samsung Biologics fits teams that want technology transfer execution translating experiment outcomes into batch record-ready and scale-ready process documentation.
Teams that treat process analytical technology as a control strategy driver
Thermo Fisher Scientific fits teams that require instrumentation-driven process analytical technology studies tied directly to control strategy recommendations and report traceability.
Sponsors needing coordinated process and analytics execution packaged for validation readiness
WuXi AppTec fits sponsors that need integrated CMC execution converging process characterization outputs with analytical validation evidence and transfer-ready documentation packages.
Organizations that need run traceability mapped to decisions and cross-team reviews
Curia fits teams that prioritize experiment planning and run traceability that maps executed runs to process parameter changes and downstream handoff artifacts.
Common Process Development sourcing mistakes that break transfer readiness
Procurement mistakes usually show up after experiment cycles when documentation does not match the decision gates needed for technology transfer. Several providers describe gaps that correlate with sponsor input discipline, scoping clarity, and internal systems integration expectations.
The pitfalls below focus on where teams misalign delivery scope to internal workflows, especially around governance, analytical method readiness, and data integration for internal capture systems.
Underestimating how much sponsor governance is required to keep change control aligned across workstreams
Lonza expects strong internal coordination so inputs and change control stay aligned across characterization, analytics, and manufacturing handoff materials. WuXi AppTec similarly requires disciplined sponsor governance because cross-workstream change control drives execution outcomes.
Scoping process analytical technology studies too loosely and creating rework between lab execution and report cycles
Thermo Fisher Scientific highlights that disciplined study scoping prevents rework between lab and report cycles. Teams that delay decision gates also risk documentation depth lag, which Samsung Biologics flags when upstream materials and testing logistics are not tightly aligned.
Assuming a provider’s reporting workflow will integrate cleanly with internal data capture without data plumbing
Quotient Sciences notes integration depth can be limited when internal systems require custom data plumbing. Teams that rely on internal systems for throughput tracking should plan for the data capture handoff workload alongside method readiness.
Treating transfer artifacts as a documentation task rather than an evidence-chain alignment task
Cambrex frames regulated tech transfer package delivery as a linkage across experiments, analytical results, and control strategy into one package, so narrow scope increases handoff friction. Lonza and WuXi AppTec both connect characterization and risk or analytics outputs into manufacturing handoff, which breaks when the evidence chain is split across unrelated vendors.
Choosing a report-centric engagement when later stages need execution-ready transfer packaging
Quotient Sciences focuses on a structured process development report used for later regulatory steps, which can limit transfer-ready packaging depth if manufacturing handoff requires broader artifacts. In contrast, Samsung Biologics and Lonza explicitly emphasize translation into batch record-ready and manufacturing handoff materials.
How analysts built the Process Development shortlist
Analysts compiled this shortlist by pulling named provider claims and delivery descriptions from the original publication entries and matching them to the ten process development service providers covered in the guide. Analysts copied each figure and retained it only when it matched the provider’s documentation and changelog, using an independent review when one was cited for that figure.
Analysts also kept provider-specific context when the descriptions aligned with the figures. Lonza is the top-ranked pick in this guide because it is consistently described as linking design space studies and risk assessment outputs into tech transfer packages for manufacturing handoff.
Frequently Asked Questions About Process Development
How do process development teams typically integrate vendor outputs with internal documentation systems?
Which providers handle analytics-to-control strategy traceability best for regulated submissions?
How does SSO and RBAC typically show up in process development project onboarding for these providers?
What data migration work is usually required when moving existing experiments into a new vendor program workflow?
Which provider fit helps when a process development team needs extensibility for changing experimental plans mid-project?
What breaks if a team cannot align internal equipment capability assumptions early?
How do vendors translate design space studies into batch record and SOP-style execution artifacts?
When should teams choose a vendor that runs both analytical development and method validation alongside process development?
How can clients establish admin controls over experiment runs and decision gates during a multi-workstream engagement?
Tools reviewed
Primary sources checked during evaluation.
Referenced in the comparison table and product reviews above.
- Science ResearchTop 10 Best Method Development Services of 2026
- Business Process OutsourcingTop 10 Best Process Consulting Services of 2026
- Biotechnology PharmaceuticalsTop 10 Best Biological Process Development Services of 2026
- Digital Transformation In IndustryTop 10 Best Development Process Software of 2026
- Data Science AnalyticsTop 10 Best Data Processing Software of 2026
Keep exploring
Comparing two specific tools?
Software Alternatives
See head-to-head software comparisons with feature breakdowns, pricing, and our recommendation for each use case.
Explore software alternatives→In this category
Science Research alternatives
See side-by-side comparisons of science research tools and pick the right one for your stack.
Compare science research tools→